Sept 3 (Reuters) – GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.<\/p>\n
\n Shares in Hong-Kong-listed HUTCHMED were up about 15% after the announcement.<\/p>\n
\n Here are more details: <\/p>\n
\n o Clinical development for HMPL-A830 will focus initially on “colorectal, pancreatic and lung cancer indications”, HUTCHMED said in a filing to the Hong Kong stock exchange.<\/p>\n
\n o A two-part clinical trial for HMPL-A830 in China will study the drug in patients with solid tumours,\u00a0records on\u00a0U.S. government registry ClinicalTrials.gov showed.<\/p>\n
\n o Solid tumours are masses of tissue that can be cancer.<\/p>\n
\n o The HUTCHMED subsidiary, HUTCHMED Ltd, is also eligible to receive additional payments tied to development, regulatory and commercial milestones of up to about $1.2 billion.<\/p>\n
\n o GlaxoSmithKline Intellectual Property (No. 4) Ltd will receive rights to develop and commercialise HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan.<\/p>\n
\n o A Phase I development programme for HMPL-A830 is expected to start in the second half of 2026, HUTCHMED said.<\/p>\n
\n o Asked what specific diseases the Phase I trials will target and in what countries they will take place, a\u00a0HUTCHMED spokesperson referred Reuters to its statement and the ClinicalTrials.gov record.<\/p>\n
\n (Reporting by Andrew Silver in Shanghai, additional reporting from Jasmeen Ara Shaikh in Bengaluru; Editing by Subhranshu Sahu)<\/p>\n","protected":false},"excerpt":{"rendered":"Sept 3 (Reuters) – GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED…\n","protected":false},"author":2,"featured_media":97133,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[20785,160],"class_list":["post-117557","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-gsk","tag-markets"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117212660489599791","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=117557"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117557\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/97133"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=117557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=117557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=117557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}